Why can’t C-19 vaccine mandates be taken seriously?
voiceforscienceandsolidarity.substack.com
First, there is no evidence that any of the C-19 vaccines proven to be efficacious in a clinical research setting will prevent the virus from successfully exploiting its evolutionary capacity when challenged by widespread immune pressure exerted by the population on the very protein that these vaccines are directed at (i.e., at spike [S] protein). However, population-level immune pressure on S protein is the inevitable consequence of mass vaccination. There isn’t even any precedent to the use of non-replicating viral vaccines in mass vaccination campaigns conducted during a pandemic, or even epidemic, of a highly mutable virus. The challenge to such an undertaking becomes even much higher when more infectious antigenic variants are already predominantly circulating as this has been the case by the time the first mass vaccination campaigns started. At least three more infectious variants were already expanding in prevalence before the campaigns were initiated (i.e., Alpha, Beta, Gamma variant). Their spread was featured by distinct temporal and geographic patterns, the underlying mechanism of which was not understood. Prior to the start of this universal vaccination program (and until today!), no single publication existed that came even close to suggesting that mass vaccination campaigns using non-transmission-blocking vaccines could be successful in extinguishing a pandemic of a highly mutable virus, let alone if several more infectious variants had already expanded in prevalence. There is ample evidence from similarly highly mutable RNA viruses like
Why can’t C-19 vaccine mandates be taken seriously?
Why can’t C-19 vaccine mandates be taken…
Why can’t C-19 vaccine mandates be taken seriously?
First, there is no evidence that any of the C-19 vaccines proven to be efficacious in a clinical research setting will prevent the virus from successfully exploiting its evolutionary capacity when challenged by widespread immune pressure exerted by the population on the very protein that these vaccines are directed at (i.e., at spike [S] protein). However, population-level immune pressure on S protein is the inevitable consequence of mass vaccination. There isn’t even any precedent to the use of non-replicating viral vaccines in mass vaccination campaigns conducted during a pandemic, or even epidemic, of a highly mutable virus. The challenge to such an undertaking becomes even much higher when more infectious antigenic variants are already predominantly circulating as this has been the case by the time the first mass vaccination campaigns started. At least three more infectious variants were already expanding in prevalence before the campaigns were initiated (i.e., Alpha, Beta, Gamma variant). Their spread was featured by distinct temporal and geographic patterns, the underlying mechanism of which was not understood. Prior to the start of this universal vaccination program (and until today!), no single publication existed that came even close to suggesting that mass vaccination campaigns using non-transmission-blocking vaccines could be successful in extinguishing a pandemic of a highly mutable virus, let alone if several more infectious variants had already expanded in prevalence. There is ample evidence from similarly highly mutable RNA viruses like